By Colin Kellaher

 

AbbVie plans to advance its lutikizumab drug candidate into Phase 3 studies in the inflammatory skin disease hidradenitis suppurativa following a successful Phase 2 trial.

AbbVie on Monday said adults who had previously failed anti-TNF therapy and received lutikizumab in the Phase 2 study showed higher response rates in key primary and secondary endpoint measures of the disease than those treated with placebo.

The North Chicago, Ill., biopharmaceutical company said there is a significant unmet medical need in hidradenitis suppurativa, a chronic and often debilitating disease that can result in lumps, abscesses and scars under the arms, in the groin and in other areas of the body.

AbbVie is studying lutikizumab in several immune-mediated diseases, including hidradenitis suppurativa and ulcerative colitis. The company last year launched a Phase 3 study of its blockbuster immunology drug Rinvoq in hidradenitis suppurativa.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

January 08, 2024 09:01 ET (14:01 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos AbbVie.
AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos AbbVie.